Dr. Emma Guttman, MD
Claim this profileIcahn School of Medicine at Mount Sinai
Affiliated Hospitals
Icahn School Of Medicine At Mount Sinai
Icahn School Of Medicine At Mount Sinai: Department Of Pediatrics Allergy & Immunology
Clinical Trials Emma Guttman, MD is currently running
Ritlecitinib
for Keloids
Keloids are common, benign cutaneous overgrowths that manifest clinically as raised, hypertrophic, often hyperpigmented lesions which are formed in response to dermal injury or idiopathic stimuli. Although keloids are a common disease, it's exact incidence and prevalence is not known. Despite the debilitating nature of keloids, current treatment modalities are limited in efficacy; there is no universally effective therapy available to patients. The research team hypothesize that ritlecitinib as a JAK3/TEC inhibitor will be able to reverse both the systemic and local keloid disease process by re-establishing immune homeostasis.
Recruiting
1 award
Phase 2
3 criteria
ShA9 Topical Gel
for Eczema
This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and adolescents with atopic dermatitis who are culture positive for S. aureus colonization. The primary safety objective of this study is to compare the safety profile of ShA9 to placebo (vehicle) over 14 weeks of application, which includes an initial two-week period of co-treatment with topical corticosteroids (TCS). The primary efficacy objective of this study is to assess the ability of ShA9, compared to placebo (vehicle), to prolong the period of atopic dermatitis control over 12 weeks after conclusion of an initial two-week period of co-treatment with TCS.
Recruiting
0 awards
Phase 1 & 2
3 criteria
More about Emma Guttman, MD
Clinical Trial Related
8 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Emma Guttman, MD has experience with
- Dupilumab
- Ritlecitinib
- Abrocitinib
- Duobrii
- GSK1070806
- Biomarker Analysis
Breakdown of trials Emma Guttman, MD has run
Atopic Dermatitis
Medical Device Dermatitis
Food Allergy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Emma Guttman, MD specialize in?
Emma Guttman, MD focuses on Atopic Dermatitis and Keloid. In particular, much of their work with Atopic Dermatitis has involved treating patients, or patients who are undergoing treatment.
Is Emma Guttman, MD currently recruiting for clinical trials?
Yes, Emma Guttman, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Emma Guttman, MD has studied deeply?
Yes, Emma Guttman, MD has studied treatments such as Dupilumab, Ritlecitinib, Abrocitinib.
What is the best way to schedule an appointment with Emma Guttman, MD?
Apply for one of the trials that Emma Guttman, MD is conducting.
What is the office address of Emma Guttman, MD?
The office of Emma Guttman, MD is located at: Icahn School of Medicine at Mount Sinai, New York, New York 10029 United States. This is the address for their practice at the Icahn School of Medicine at Mount Sinai.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.